3/7
08:17 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $150.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $150.00 price target on the stock.
3/3
11:02 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/28
10:04 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock.
2/28
08:49 am
bpmc
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress [Yahoo! Finance]
Medium
Report
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress [Yahoo! Finance]
2/28
08:00 am
bpmc
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
Medium
Report
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
2/24
01:26 pm
bpmc
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now [Yahoo! Finance]
2/22
02:12 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/22
02:12 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/14
10:01 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/14
10:09 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
2/14
08:07 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
2/13
11:35 pm
bpmc
Q4 2024 Blueprint Medicines Corp Earnings Call [Yahoo! Finance]
Low
Report
Q4 2024 Blueprint Medicines Corp Earnings Call [Yahoo! Finance]
2/13
06:37 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock, up previously from $124.00.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $128.00 price target on the stock, up previously from $124.00.
2/13
11:47 am
bpmc
Blueprint Medicines Corporation 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
Blueprint Medicines Corporation 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/13
10:11 am
bpmc
Blueprint Medicines: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Blueprint Medicines: Q4 Earnings Snapshot [Yahoo! Finance]
2/13
08:53 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
2/13
07:37 am
bpmc
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results [Yahoo! Finance]
Low
Report
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results [Yahoo! Finance]
2/13
07:00 am
bpmc
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Medium
Report
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
2/6
07:20 pm
bpmc
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? [Yahoo! Finance]
Medium
Report
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? [Yahoo! Finance]
2/5
08:32 am
bpmc
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 [Yahoo! Finance]
Low
Report
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 [Yahoo! Finance]
2/5
08:00 am
bpmc
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Low
Report
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
2/4
10:28 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JPMorgan Chase & Co. from $126.00 to $129.00. They now have an "overweight" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JPMorgan Chase & Co. from $126.00 to $129.00. They now have an "overweight" rating on the stock.
1/27
10:19 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Piper Sandler from $109.00 to $119.00. They now have a "neutral" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Piper Sandler from $109.00 to $119.00. They now have a "neutral" rating on the stock.
1/15
10:47 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
1/14
07:15 am
bpmc
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? [Yahoo! Finance]
Low
Report
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? [Yahoo! Finance]